Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

Neuropsychopharmacology

Volumn 42, Issue 4, 2017, Pages 844-853

  Sanacora, Gerard ^a   Johnson, Michael R ^b   Khan, Arif ^c,d   Atkinson, Sarah D ^e   Riesenberg, Robert R ^f   Schronen, Juan P ^g   Burke, Michael A ^h   Zajecka, John M ⁱ   Barra, Luis ^j   Su, Hong Lin ^k   Posener, Joel A ^k   Bui, Khanh H ^k   Quirk, Michael C ^k   Piser, Timothy M ^k   Mathew, Sanjay J ^l,m   Pathak, Sanjeev ^k  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sarkis Clinical Trials   (United States)

^c Northwest Clinical Research Center   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Finger Lakes Clinical Research   (United States)

^f Atlanta Center for Medical Research   (United States)

^g Welgemoed Medical Centre   (South Africa)

^h Atlanta Research Center   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSIDAD DE ANTOFAGASTA   (Chile)

^k ASTRAZENECA   (United Kingdom)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LANICEMINE; PLACEBO; PHENETHYLAMINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALCOHOL INTOXICATION; ANEMIA; ANXIETY DISORDER; ARTICLE; ASTHMA; ATTENTION; ATTENTION DISTURBANCE; BLURRED VISION; BRADYPHRENIA; BRONCHITIS; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPERSONALIZATION; DEPRESSION; DEPRESSION ASSESSMENT; DEVELOPMENTAL COORDINATION DISORDER; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DISSOCIATIVE DISORDER; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MISUSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSARTHRIA; ECG ABNORMALITY; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; GASTRITIS; HEPATITIS C; HUMAN; ILLUSION; LEARNING; LEARNING DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY DISORDER; MENTAL PATIENT; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT HISTORY OF THERAPY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUICK INVENTORY OF DEPRESSIVE SYMPTOMOLOGY SELF REPORT SCORE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; REMISSION; SCORING SYSTEM; SEDATION; SENSORY DYSFUNCTION; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL HALLUCINATION; WORKING MEMORY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; TREATMENT RESISTANT DEPRESSION;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHENETHYLAMINES; PYRIDINES;

EID: 84994165273     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.224     Document Type: Article

References (24)

1. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD et al (2009). Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14: 197-206.
2. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK et al (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843-853.
3. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125-136.
4. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK et al (2013). GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38: 729-742.
5. Chowdhury GM, Zhang J, Thomas M, Banasr M, Ma X, Pittman B et al (2016). Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant-like effects. Mol Psychiatry (e-pub ahead of print 12 April 2016; doi:10.1038/mp.2016.34).
6. Emnett CM, Eisenman LN, Taylor AM, Izumi Y, Zorumski CF, Mennerick S (2013). Indistinguishable synaptic pharmacodynamics of the N-methyl-D-aspartate receptor channel blockers memantine and ketamine. Mol Pharmacol 84: 935-947.
7. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC et al (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303: 47-53.
8. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health: Rockville, MD.
9. Iovieno N, Papakostas GI (2012). Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry 73: 1300-1306.
10. Khan A, Bhat A, Faucett J, Kolts R, Brown WA (2011). Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity. Psychopharmacology (Berl) 214: 961-965.
11. Khan A, Khan S, Brown WA (2002a). Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 5: 193-197.
12. Khan A, Leventhal RM, Khan SR, Brown WA (2002b). Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22: 40-45.
13. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011). Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 72: 464-472.
14. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
15. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS et al (2008). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebocontrolled study. J Clin Psychopharmacol 28: 156-165.
16. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW (2015). A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 45: 693-704.
17. Naudet F, Maria AS, Falissard B (2011). Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One 6: e20811.
18. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB (2015). Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172: 950-966.
19. Oquendo MA, Baca-Garcia E, Kartachov A, Khait V, Campbell CE, Richards M et al (2003). A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry 64: 825-833.
20. Papakostas GI, Ostergaard SD, Iovieno N (2015). The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 76: 456-466.
21. Sanacora G, Schatzberg AF (2015). Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 40: 259-267.
22. Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ et al (2014). Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19: 978-985.
23. Schatzberg AF (2014). A word to the wise about ketamine. Am J Psychiatry 171: 262-264.
24. Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I et al (2013). A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74: 257-264.